Korsana Biosciences, Inc.
KRSAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Korsana Biosciences, Inc. (KRSA) is listed under Biotechnology. With a market capitalization of $1.43B, it sits in small-cap territory. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system.
Market Cap
$1.43B
Beta
1.73
P/E (TTM)
—
P/E (Fwd)
-8.80
EPS (TTM)
$-7.07
EPS (Fwd)
$-3.56
ROE
—
ROA
—
Cash
$134.2M
Total Debt
$1.1M
Free CF
—
52W Change
113.0%
Annual Financials
Cash vs Debt
Where KRSA stands vs its 150-day and 200-day moving averages
As of the October 1, 2026 close, KRSA finished 39.92% above its 150-day moving average ($22.87) and 63.27% above its 200-day moving average ($19.60). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KRSA overbought or oversold?
At the October 1, 2026 close, KRSA's RSI(14) was 60.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $134.2M in cash comfortably exceeding the $1.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods.
With a beta above 1.5, KRSA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Korsana Biosciences, Inc. and its sector.